

Certificate of Analysis

Analysezertifikat


Certificat d'Analyse

Product name	C5/C5a des-arg, Human, clone 2942		
Catalog number	TE2078-100UG		
Lot number	xxxxxXxxxx	Expiry date	MMM YYYY
Volume	1 ml	Amount	100 µg
Formulation	0.2 µm filtered in PBS+0.1%BSA	Concentration	100 µg/ml
Host Species	Mouse IgG2a	Conjugate	None
Endotoxin	<24 EU/mg	Purification	Protein G
Storage	4°C		

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #	1							
Yes	•				•	•		•
No								
N.D.		•	•	•			•	

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot



W: Specificity test of TE2078. TE2078 was used in different concentrations and recognizes C5a (14kDa).

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

- W: A reduced sample treatment and SDS-Page was used. The band size is 14 kDa .
- IHC-F: Tissue sections were fixed in Histochoice MB and treated with levamisole to quench endogenous alkaline phosphatases. As negative control the primary antibody was omitted (Ref.1).
- Positive control: Eye tissue of patient with AMD (Ref.1); Negative control: Eye tissue of patient without AMD (Ref.1).
- General comment: Please notice that under given conditions it is known that C5 can expose epitopes normally only found in the cleaved activation products (ref.2).

General Information

Description

Monoclonal antibody 2942 reacts with a neo-epitope on human C5a/C5a des-Arg that is formed by proteolytic cleavage of C5 into C5a and C5b during complement activation. C5a is a single chain glycopeptide composed of 74-amino-acids, which is rapidly converted to the less potent derivative C5a des-Arg upon removal of the C-terminal arginine by carboxypeptidase B. C5a acts as a potent anaphylatoxin by binding to its high affinity receptor C5aR (or CD88) on the membrane of target cells inducing smooth muscle contraction, increased vascular permeability, degranulation of mast cells and basophils, and the release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. Elevation of C5a is associated with increased cardiovascular risk in patients with advanced atherosclerosis. Also, C5a is closely associated with the capillary leak syndrome in leukemic children after bone marrow transplantation. C5a is also a marker in urine for predicting the onset of

acute graft rejection after kidney transplantation and has been shown to be present in extracellular deposits in patients suffering from age-related macular degeneration (AMD). Please be aware that under given conditions it is known that C5 can expose epitopes normally only found in the cleaved activation products (ref.2).

- References**
1. Nozaki, M et al; Drusen complement components C3a and C5a promote choroidal neovascularisation. PNAS 2006, 103: 2328
 2. Nilsson, P et al, A novel human whole blood model preventing fibrin formation reveals that thrombin does not cleave C5 under physiological conditions. Abstract Mol Immunol 2018, 102: 194

Storage&stability Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.

Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC

Date

Do you have any questions or comments regarding this product? Please contact us via info@tecomedical.com

www.tecomedical.com



A EUROBIO SCIENTIFIC COMPANY

Switzerland
TECOmedical AG
Gewerbestrasse 10
4450 Sissach
Phone +41 61 985 81 00
Fax +41 61 985 81 09
Mail info@tecomedical.com

Germany
TECOmedical GmbH
Wasserbreite 57
32257 Bünde
Phone +49 52 23 985 99 99
Fax +49 52 23 985 99 98
Mail info@tecomedical.com

Benelux
TECOmedical Benelux BV
Computerweg 22
3542 DR Utrecht, The Netherlands
Phone +31 30 307 87 30
Fax +31 30 307 49 39
Mail benelux@tecomedical.com

Austria
TECOmedical AG
Phone 0800 20 40 66
Fax 0800 20 40 55
Mail info@tecomedical.com